HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) issued its quarterly earnings results on Tuesday. The medical research company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60), Morningstar.com reports. HTG Molecular Diagnostics had a negative net margin of 440.31% and a negative return on equity of 1,538.49%. The firm had revenue of $1.76 million during the quarter, compared to analyst estimates of $1.80 million.

HTG Molecular Diagnostics (NASDAQ HTGM) traded down 2.17% during midday trading on Wednesday, reaching $2.25. 465,377 shares of the company’s stock traded hands. HTG Molecular Diagnostics has a 52 week low of $1.20 and a 52 week high of $13.25. The company’s 50-day moving average price is $2.58 and its 200 day moving average price is $3.37. The stock’s market capitalization is $21.43 million.

WARNING: “HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Announces Quarterly Earnings Results, Meets Estimates” was first reported by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/09/htg-molecular-diagnostics-inc-nasdaqhtgm-announces-quarterly-earnings-results-meets-estimates.html.

HTGM has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of HTG Molecular Diagnostics in a research report on Thursday, June 29th. ValuEngine lowered shares of HTG Molecular Diagnostics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 6th. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research report on Thursday, May 11th. Rodman & Renshaw upped their price target on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, May 16th. Finally, Canaccord Genuity upped their price target on shares of HTG Molecular Diagnostics from $5.50 to $6.50 and gave the stock a “hold” rating in a research report on Wednesday, April 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $5.75.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Earnings History for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.